Detailed information for compound 268775
Basic information
Technical information
- TDR Targets ID: 268775
- Name: 3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methy l]-1-benzofuran-4-yl]oxy]-N-(pyridin-3-ylmeth yl)propan-1-amine
- MW: 456.457 | Formula: C25H23F3N2O3
-
H donors: 1
H acceptors: 1
LogP: 4.81
Rotable bonds: 10
Rule of 5 violations (Lipinski): 1 - SMILES: Fc1ccc(c(c1F)F)OCc1oc2c(c1C)c(OCCCNCc1cccnc1)ccc2
- InChi: 1S/C25H23F3N2O3/c1-16-22(15-32-21-9-8-18(26)24(27)25(21)28)33-20-7-2-6-19(23(16)20)31-12-4-11-30-14-17-5-3-10-29-13-17/h2-3,5-10,13,30H,4,11-12,14-15H2,1H3
- InChiKey: FKIAZUIISXQFHC-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 3-[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]benzofuran-4-yl]oxy-N-(3-pyridylmethyl)propan-1-amine
- 3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-4-benzofuranyl]oxy]-N-(3-pyridylmethyl)-1-propanamine
- 3-[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]benzofuran-4-yl]oxypropyl-(3-pyridylmethyl)amine
- 3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-4-benzofuranyl]oxy]-N-(3-pyridylmethyl)propan-1-amine
- 3-Pyridinemethanamine, N-[3-[[3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-4-benzofuranyl]oxy]propyl]-
- AIDS-115230
- AIDS115230
- RO-09-4879
- RO-0904879
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | N-myristoyltransferase 2 | References | |
| Candida albicans | myristoyl-CoA:protein N-myristoyltransferase that is capable of functional substitution for S. cerevisiae NMT1 (YLR195C) | Starlite/ChEMBL | References |
| Homo sapiens | N-myristoyltransferase 1 | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Trypanosoma brucei | N-myristoyl transferase, putative | 0.0648 | 0.3364 | 0.5 |
| Echinococcus multilocularis | dihydrofolate reductase | 0.1086 | 1 | 1 |
| Loa Loa (eye worm) | dihydrofolate reductase | 0.1086 | 1 | 1 |
| Trypanosoma cruzi | N-myristoyl transferase, putative | 0.0648 | 0.3364 | 0.5 |
| Echinococcus granulosus | dihydrofolate reductase | 0.1086 | 1 | 1 |
| Mycobacterium leprae | DIHYDROFOLATE REDUCTASE DFRA (DHFR) (TETRAHYDROFOLATE DEHYDROGENASE) | 0.1086 | 1 | 0.5 |
| Giardia lamblia | CDC72 | 0.0648 | 0.3364 | 0.5 |
| Leishmania major | N-myristoyl transferase, putative | 0.0648 | 0.3364 | 0.5 |
| Plasmodium falciparum | glycylpeptide N-tetradecanoyltransferase | 0.0648 | 0.3364 | 0.5 |
| Trichomonas vaginalis | N-myristoyl transferase, putative | 0.0648 | 0.3364 | 1 |
| Trypanosoma brucei | N-myristoyltransferase | 0.0648 | 0.3364 | 0.5 |
| Entamoeba histolytica | glycylpeptide N-tetradecanoyltransferase, putative | 0.0648 | 0.3364 | 0.5 |
| Mycobacterium tuberculosis | Dihydrofolate reductase DfrA (DHFR) (tetrahydrofolate dehydrogenase) | 0.1086 | 1 | 0.5 |
| Trypanosoma cruzi | N-myristoyl transferase, putative | 0.0648 | 0.3364 | 0.5 |
| Plasmodium vivax | glycylpeptide N-tetradecanoyltransferase, putative | 0.0648 | 0.3364 | 0.5 |
| Brugia malayi | Dihydrofolate reductase | 0.1086 | 1 | 1 |
| Mycobacterium ulcerans | dihydrofolate reductase DfrA | 0.1086 | 1 | 0.5 |
| Chlamydia trachomatis | dihydrofolate reductase | 0.1086 | 1 | 0.5 |
| Schistosoma mansoni | dihydrofolate reductase | 0.1086 | 1 | 1 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| AUC (ADMET) | = 330 ng hr ml-1 | Pharmacokinetic property of the compound was determined | ChEMBL. | 12467623 |
| AUC (ADMET) | = 330 ng hr ml-1 | Plasma concentration expressed as area under curve after intravenous administration was determined in rat | ChEMBL. | 11844682 |
| ED50 (functional) | = 7.1 mg kg-1 | In vivo efficacy expressed as effective dose of the compound against murine systematic candidiasis model | ChEMBL. | 12467623 |
| ED50 (functional) | = 7.1 mg kg-1 | Effective dose required against C. albicans for 50% survival on intravenous administration in rats | ChEMBL. | 11844682 |
| ED50 (functional) | = 7.1 mg kg-1 | In vivo efficacy expressed as effective dose of the compound against murine systematic candidiasis model | ChEMBL. | 12467623 |
| IC50 (binding) | = 3.7 nM | Inhibitory activity against C. albicans (Nmt) assessed as inhibitory concentration (nM); 3.7-9.4 nM | ChEMBL. | 11844682 |
| IC50 (binding) | = 3.7 nM | Inhibitory activity against C. albicans (Nmt) assessed as inhibitory concentration (nM); 3.7-9.4 nM | ChEMBL. | 11844682 |
| IC50 (binding) | = 0.0056 uM | Inhibitory activity of the compound against Candida albicans Nmt (CaNmt) | ChEMBL. | 12467623 |
| IC50 (binding) | = 0.0056 uM | Inhibitory activity of the compound against Candida albicans Nmt (CaNmt) | ChEMBL. | 12467623 |
| IC50 (binding) | = 0.0057 uM | Inhibitory activity against C. albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 microM | ChEMBL. | 11844682 |
| IC50 (binding) | = 0.0057 uM | Inhibition of Candida albicans N-myristoyltransferse | ChEMBL. | 17349719 |
| IC50 (binding) | = 0.0057 uM | Inhibitory activity against C. albicans N-Myristoyltransferase (CaNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 microM | ChEMBL. | 11844682 |
| IC50 (binding) | = 0.0057 uM | Inhibition of Candida albicans N-myristoyltransferse | ChEMBL. | 17349719 |
| IC50 (functional) | = 0.035 uM | In vitro antifungal activity of the compound against Candida albicans (CY1002) | ChEMBL. | 12467623 |
| IC50 (functional) | = 0.035 uM | Antifungal activity expressed as inhibitory concentration against C. albicans CY1002 in YNBPB medium | ChEMBL. | 11844682 |
| IC50 (functional) | = 0.035 uM | In vitro antifungal activity of the compound against Candida albicans (CY1002) | ChEMBL. | 12467623 |
| IC50 (functional) | = 0.035 uM | Antifungal activity expressed as inhibitory concentration against C. albicans CY1002 in YNBPB medium | ChEMBL. | 11844682 |
| IC50 (functional) | = 0.33 uM | Antifungal activity expressed as inhibitory concentration against C. albicans CY1002 in calf serum | ChEMBL. | 11844682 |
| IC50 (functional) | = 0.33 uM | Antifungal activity expressed as inhibitory concentration against C. albicans CY1002 in calf serum | ChEMBL. | 11844682 |
| IC50 (binding) | > 430 uM | Inhibitory activity against human N-Myristoyltransferase (HsNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 microM | ChEMBL. | 11844682 |
| IC50 (binding) | > 430 uM | Inhibitory activity against human N-Myristoyltransferase (HsNmt) assessed as inhibitory concentration using substrate peptide and myristotyl-CoA at 0.5 microM | ChEMBL. | 11844682 |
| Log IC50 (binding) | = 2.244 uM | Inhibition of Candida albicans N-myristoyltransferse | ChEMBL. | 17349719 |
| Log IC50 (binding) | = 2.244 uM | Inhibition of Candida albicans N-myristoyltransferse | ChEMBL. | 17349719 |
| MIC80 (functional) | = 0.125 ug ml-1 | Antifungal activity against Candida albicans by serial dilution method | ChEMBL. | 20615585 |
| MIC80 (functional) | = 0.5 ug ml-1 | Antifungal activity against Cryptococcus neoformans by serial dilution method | ChEMBL. | 20615585 |
| T1/2 (ADMET) | = 2 hr | Half life period of the compound was evaluated in rat plasma | ChEMBL. | 12467623 |
| T1/2 (ADMET) | = 2 hr | Half life of compound determined after intravenous administration to rat | ChEMBL. | 11844682 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Candida albicans | ChEMBL23 | 11844682 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL347048
- PubChem: 491351
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.